Drug Trial Radar · NCT07743112
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Sep 5, 2025
Primary completion
Sep 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.
Conditions
- Acute Myeloid Leukemia
Interventions
MAX-40279Drug
Dose escalation:MAX-40279: 40 mg, 50 mg, and 60 mg twice daily (BID). Dose expantion: MAX-40279 RP2D. Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter. Azacitidine: 75 mg/m2 days 1-7. 28 days are one cycle.
AzacitidineDrug
Given by IV, 75 mg/m2
VenetoclaxDrug
100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Dose escalation; an average of 6 months.
- Adverse events (AEs), serious adverse events (SAEs)Time frame: Through study completion; an average of 24 months.
- Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)Time frame: Dose escalation; an average of 6 months.
- CRcTime frame: Through study completion; an average of 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Institute of Hematology & Blood Diseases Hospital ( Chinese Academy of Medical Sciences)
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.